Clinical trial · Interventional
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to make up for the gap by performing a dynamic scan of \<Sup\>18\<Sup\>F-FDG PET/CT on newly diagnosed patients with papillary thyroid carcinoma. Pathological and genomic studies are performed. The differences between metastatic central lymph nodes images and tissues are compared at the same time. \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging is explored in metastatic central lymph nodes with papillary thyroid cancer for the diagnostic value.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymph Node Metastases | — | UNRESOLVED | — |
| Positron-Emission Tomography | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| B-ultrasonography | Diagnostic Test | — | UNRESOLVED |
| <Sup>18<Sup>F-FDG PET/CT dynamic scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- <Sup>18<Sup>F-FDG PET/CT study group
- description
- \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scan The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
- interventionNames
- Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan
- type
- OTHER
- label
- B-ultrasonography group
- description
- B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * • Accurately diagnosing primary papillary thyroid cancer according to pathological diagnostic criteria . * Thyroid papillary carcinoma was suspected by thyroid ultrasound text and/or neck CT. * The age is more than 18 years old and less than 65 years old. There is no gender restriction. * Untreated patients who have not received surgery, interventional therapy,chemotherapy, biotherapy, and radiation therapy. * Physical condition score of Eastern Cooperative Oncology Group(ECOG): 0-2; no major organ dysfunction; oxygen partial pressure ≥ 10.64 kilopascal(kPa); white blood cell count≥ 4 × 109/L; hemoglobin≥ 9.5g/dL; neutrophil absolute count ≥ 1.5 × 109 / L; platelet count ≥ 100× 109 / L; total bilirubin ≤ 1.5 times of the upper limit of normal value;creatinine ≤ 1.25 times of the upper limit of normal value; and creatinine clearance ≥ 60ml / min. * Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent. Exclusion Criteria: * • Poorly controlled diabetics (fasting blood glucose levels \> 200 mg/dL).• In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years.• Breastfeeding and/or pregnant women. * Patients with severe bleeding tendencies (prothrombin time less than 50%,cannot be corrected by treatment with vitamin K, etc.). * Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate. * People with severe emphysema, pulmonary congestion, and pulmonary heart disease. * Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons).
References
Publications (0)
Data not yet available